PDS Biotech Announces PDS0101 Combined With Chemoradiotherapy Associated With Rapid Decline In Circulating Tumor DNA (ctDNA/cfDNA)
Portfolio Pulse from Benzinga Newsdesk
PDS Biotech has announced that its lead candidate PDS0101, when combined with standard-of-care chemoradiotherapy, was associated with a rapid decline in human papillomavirus (HPV) circulating cell-free DNA, a potential predictive biomarker of treatment response. The data was presented at the ASTRO 2023 Annual Meeting. The study evaluated the relationship between the levels of circulating cfHPV-DNA and the extent of disease, clinical staging, and treatment response in patients with HPV-positive cervical cancer.
October 02, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PDS Biotech's PDS0101 shows promising results in the treatment of HPV-positive cervical cancer. The data suggests a potential positive impact on the company's stock.
The positive results from the study of PDS0101, PDS Biotech's lead candidate, could potentially lead to increased investor confidence and a rise in the company's stock price. The data suggests that PDS0101 could be a significant product for the company, which could have a positive impact on its financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100